Harrison CN et al. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. Br J Haematol 2022;198(2):317-27. Abstract

Harrison CN et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomised, open-label, phase 3 trial. Lancet Haematol 2018;5(2):e73-81. Abstract

Harrison C et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98. Abstract

Mascarenhas J et al. BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis — JAK inhibitor-naïve or with suboptimal response to ruxolitinib — Preliminary data from the MANIFEST study. EHA 2022;Abstract S198.

Mesa R et al. MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. ASCO 2022;Abstract 7002.

Mesa R et al. Overall survival in the SIMPLFY-1 and SIMPLFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia 2022;36(9):2261-8. Abstract

Passamonti F et al. Navitoclax plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study. EHA 2022;Abstract S197.

Verstovsek S et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807. Abstract

Yacoub A et al. Add-on parsaclisib (a PI3K-delta inhibitor) in patients with myelofibrosis and suboptimal response to ruxolitinib: Interim analysis from a Phase 2 study. EHA 2022;Abstract EP1075.